Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Ruanyun Edai Technology Inc. (NASDAQ:RYET) (the "Company") today announced that it received a written notice dated October 7, 2026 from Nasdaq stating that the closing bid price of its ordinary shares was below
Ruanyun Edai Technology Inc. (NASDAQ: RYET) has signed a definitive agreement to grant BioNexus Gene Lab Corp. (NASDAQ: BGLC) an exclusive 10-20 year license for its Cogni AI document-intelligence platform in Malaysian healthcare. RYET will receive 560,000 BGLC shares and a 10% royalty on qualifying technology receipts. The deal aligns with Malaysia's RM1 billion healthcare digitalization initiative, though neither company has secured government contracts yet.
Ruanyun Edai Technology Inc. (NASDAQ:RYET) ("Ruanyun" or the "Company") today announced that it expects preliminary unaudited revenue in the range of approximately US$9.3 million to US$9.5 million